Review summary
Teaching objective: Find lung cancer early in a 65-year-old Black man who has smoked a pack a day for 35 years and who was never offered screening: confirm eligibility on the USPSTF 1974 criteria (50 to 80 years, 20 pack-years or more, smoking now or quit within 15 years), hold the shared decision-making visit with a decision aid and tobacco treatment that the CMS coverage decision requires, read the low-dose CT with Lung-RADS, and work up a category 4X nodule without delay: PET-CT, brain MRI, systematic EBUS staging of the mediastinum (ACCP), and tissue for PD-L1 and comprehensive biomarker testing before any immunotherapy. Then treat resectable stage IIB adenocarcinoma on the NCCN guideline: tumor board review, physiologic evaluation for lobectomy (ACCP), three cycles of nivolumab with carboplatin and pemetrexed before surgery (CheckMate 816), immune-related adverse event monitoring, thoracoscopic lobectomy with lymph node dissection, and surveillance CT; treat tobacco dependence with varenicline even after the diagnosis; and track each step for delay, because Black Americans are less often found eligible for and offered screening and less often offered surgery for early lung cancer.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| September 12, 1913 | Born in Oakville, Alabama, to a sharecropping family. | CLM-0001 |
| about 1920 | Nearly dies of pneumonia at about 7, in an epidemic in which a brother and a sister die; the family soon moves to Cleveland. | CLM-0002 |
| 1933 | National interscholastic records; enters the Ohio State University, where he is barred from the dormitory because of his race. | CLM-0003, CLM-0004 |
| August 1936 | Four gold medals at the Berlin Olympic Games. | CLM-0005 |
| 1939 | Files for personal bankruptcy after a business fails; years of hardship and exclusion follow the Games. | CLM-0006 |
| 1972 | Moves with his wife from Chicago to the Phoenix area. | CLM-0007 |
| 1976 | Presidential Medal of Freedom; a pack-a-day smoker for decades. | CLM-0008, CLM-0009 |
| December 12, 1979 | Admitted in Chicago with shortness of breath; inoperable adenocarcinoma of the left lung diagnosed; chemotherapy in Chicago and Tucson. | CLM-0010 |
| March 31, 1980 | Dies of lung cancer in Tucson at 66. | CLM-0011 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | James Cleveland (J.C.) Owens was born on September 12, 1913, in Oakville, Alabama, the youngest of the children of Henry and Mary Emma Owens, who were sharecroppers. The Ohio State University Libraries give ten children; contemporary newspaper accounts and his own account give nine. The documented date used for the synthetic date of birth. The number of children differs between sources and is recorded as given. |
confirmed | Jesse Owens: A Lasting Legend. Growing Up supports Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports HISTMED Master Roster v3 context |
| D | As a child in Alabama he worked in the fields with his family. At about 7 he had pneumonia and nearly died; a brother and a sister died during the same epidemic. He later described himself as a sickly, emaciated, poverty-stricken child, and said that his parents knew the family had to leave to survive. In the early 1920s the family moved north to Cleveland, following an older sister who had written home about jobs there. His own published account, repeated in contemporary newspaper obituaries, with the move dated by the Ohio State University Libraries. Anchors the past medical history (childhood pneumonia) and the family history. |
probable | Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports Jesse Owens: A Lasting Legend. Growing Up supports |
| D | In Cleveland a teacher misheard his initials J.C. and called him Jesse, and the name stuck. Coached by Charles Riley from junior high school, he won the long jump, set a world record in the 220-yard dash and tied the world record in the 100-yard dash at the National Interscholastic Championship in 1933. | confirmed | Jesse Owens: A Lasting Legend. Growing Up supports |
| D | At the Ohio State University, which he entered in 1933, he was barred from the men's dormitory because of his race, lived in a boarding house with other African American students, and could not eat in the restaurants along High Street. He worked as a freight elevator operator. At the Big Ten championships in May 1935 he set world records in the 220-yard dash, the 220-yard low hurdles and the long jump. Documented racial discrimination in his education; it anchors the social history and the plan's attention to equity. |
confirmed | Jesse Owens: A Lasting Legend. Owens and The Ohio State University supports Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports |
| D | At the 1936 Olympic Games in Berlin he won four gold medals, in the 100 meters, the 200 meters, the long jump and the 4 x 100-meter relay, and he was given a ticker-tape parade in New York on his return. | confirmed | Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports Jesse Owens: A Lasting Legend. Owens' Legacy: a National Icon supports |
| D | The offers that followed the Games did not become steady work. He earned money racing against horses and local sprinters, and said that Black athletes were not allowed in any professional sport then. A dry-cleaning business he founded in 1938 went into debt, and he filed for personal bankruptcy in 1939. He owed taxes on his income after the Games, and decades later was in trouble with the Internal Revenue Service again for failing to file returns. He later worked through public relations firms, as a speaker, and with youth organizations. Documented years of financial hardship and racial exclusion after the Games. Anchors the modern social history (speaking and youth work) and the plan's attention to cost and access. |
confirmed | Jesse Owens: A Lasting Legend. Owens' Legacy: a National Icon supports Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports |
| D | He met Minnie Ruth Solomon at Fairmount Junior High School in Cleveland in 1930; they married and had three daughters. In the early 1970s, with their children grown, they moved from Chicago, their home of more than 20 years, to the Phoenix area of Arizona. Ruth Owens died in 2001. Anchors the modern household. His daughters are not named and no relative is given a role or a health fact in the modern episode. |
confirmed | Jesse Owens: A Lasting Legend. The Owens Family supports Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports |
| D | The Ohio State University awarded him an honorary doctorate of athletic arts, and in 1976 he received the Presidential Medal of Freedom. He served on the board of directors of the U.S. Olympic Committee from 1973. | confirmed | Jesse Owens: A Lasting Legend. Owens and The Ohio State University supports Jesse Owens: A Lasting Legend. Owens' Legacy: a National Icon supports Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports |
| D | He smoked cigarettes for decades: at his death newspapers described him as a pack-a-day smoker for the past 35 years, and his doctors said he had smoked about a pack a day. The Ohio State University Libraries call him a lifetime smoker. About 35 pack-years, the figure used for the modern smoking history; it meets the 2021 USPSTF screening threshold of 20 pack-years. The start year is not documented. |
probable | Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports Jesse Owens: A Lasting Legend. The Owens Family supports |
| D | He was admitted to Michael Reese Hospital in Chicago on December 12, 1979, after reporting shortness of breath; the illness was diagnosed as adenocarcinoma of the left lung, described as inoperable. He received chemotherapy, was moved when he was able to travel to University Hospital in Tucson, and had outpatient chemotherapy at the University of Arizona Cancer Center, with breathlessness and difficulty talking. The documented diagnosis to which the synthetic modern adenocarcinoma of the left upper lobe is linked. In the modern episode the cancer is found by screening at an earlier stage, which is the teaching contrast. |
confirmed | Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports Jesse Owens: A Lasting Legend. The Owens Family supports |
| D | He died of lung cancer on March 31, 1980, at 66, at the University of Arizona Health Sciences Center in Tucson, about three and a half months after he was first admitted, with his wife at his side. History only, after the true-frame episode; stated without detail. |
confirmed | Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) supports Jesse Owens: A Lasting Legend. The Owens Family supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | active | CLM-0009 |
| S | Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | both_with_link | CLM-0010, CLM-0011 |
| S | Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | resolved | confirmed | both_with_link | CLM-0009 |
| S | Acute viral upper respiratory infection (rhinovirus on a respiratory panel) on day 13 of cycle 2 of chemoimmunotherapy: runny nose, sore throat and a dry cough for three days, no hypoxia, clear chest X-ray; immune-related pneumonitis and pneumonia excluded; resolved | resolved | confirmed | active | |
| S | After thoracoscopic left upper lobectomy with mediastinal and hilar lymph node dissection: ypT1a N0 (0 of 16 nodes), R0, major pathologic response (6 percent residual viable tumor) | active | confirmed | active | CLM-0010, CLM-0011 |
| S | Nicotine dependence, cigarettes, in early remission: no cigarettes since day 1 of cycle 1, about four months, on varenicline | active | confirmed | both_with_link | CLM-0009 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1979-05-11 | Hemoglobin [Mass/volume] in Blood | 15.1 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 1979-05-11 | Leukocytes [#/volume] in Blood by Automated count | 8.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1979-05-11 | Platelets [#/volume] in Blood by Automated count | 262 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1979-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1979-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1979-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 1 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 1979-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1979-05-11 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1979-05-11 | Calcium [Mass/volume] in Serum or Plasma | 9.4 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 1979-05-11 | Albumin [Mass/volume] in Serum or Plasma | 4.2 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1979-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 1979-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 1979-05-11 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 1979-05-11 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1979-05-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1979-05-26 | Hemoglobin [Mass/volume] in Blood | 14.9 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 1979-05-26 | Leukocytes [#/volume] in Blood by Automated count | 8.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1979-05-26 | Neutrophils [#/volume] in Blood by Automated count | 5.2 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1979-05-26 | Platelets [#/volume] in Blood by Automated count | 258 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1979-05-26 | Creatinine [Mass/volume] in Serum or Plasma | 1 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 1979-05-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1979-05-26 | Glucose [Mass/volume] in Serum or Plasma | 97 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1979-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 1979-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 1979-05-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1979-05-26 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 1979-05-26 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1979-05-26 | Cortisol [Mass/volume] in Serum or Plasma | 13.8 ug/dL Reference Morning (8 a.m.) reference interval |
http://loinc.org · 2143-6 |
| S | 1979-05-26 | FEV1 | 2.71 L Reference Lower limit of normal for his age and height (GLI 1965) |
http://loinc.org · 20150-9 |
| S | 1979-05-26 | FEV1 measured/predicted | 86% Reference >=80% |
http://loinc.org · 20152-5 |
| S | 1979-05-26 | FEV1/FVC | 0.73 Reference Below 0.70 after bronchodilator indicates airflow obstruction |
http://loinc.org · 19926-5 |
| S | 1979-05-26 | Diffusion capacity.carbon monoxide | 23.6 mL/min/mm[Hg] Reference Lower limit of normal for his age and height; predicted 27.4 |
http://loinc.org · 19911-7 |
| S | 1979-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 1979-05-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | http://loinc.org · 70274-6 |
| S | 1979-06-24 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 1979-06-24 | Leukocytes [#/volume] in Blood by Automated count | 6.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1979-06-24 | Neutrophils [#/volume] in Blood by Automated count | 4.1 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1979-06-24 | Platelets [#/volume] in Blood by Automated count | 214 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1979-06-24 | Creatinine [Mass/volume] in Serum or Plasma | 1 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 1979-06-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1979-06-24 | Glucose [Mass/volume] in Serum or Plasma | 101 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1979-06-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 1979-06-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 1979-06-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1979-06-24 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 1979-06-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1979-06-24 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 1979-08-05 | Hemoglobin [Mass/volume] in Blood | 12.8 g/dL (low) Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 1979-08-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1979-08-05 | Neutrophils [#/volume] in Blood by Automated count | 3.6 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1979-08-05 | Platelets [#/volume] in Blood by Automated count | 188 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1979-08-05 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1979-08-05 | Potassium [Moles/volume] in Serum or Plasma | 4.3 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1979-08-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.1 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 1979-08-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 74 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1979-08-05 | Glucose [Mass/volume] in Serum or Plasma | 95 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1979-08-05 | Calcium [Mass/volume] in Serum or Plasma | 9.3 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 1979-08-05 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1979-08-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 1979-08-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 1979-08-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 90 U/L Reference 40-129 U/L |
http://loinc.org · 6768-6 |
| S | 1979-08-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1979-08-05 | Thyrotropin [Units/volume] in Serum or Plasma | 6.8 mIU/L (high) Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 1979-08-05 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1979-08-05 | Cortisol [Mass/volume] in Serum or Plasma | 12.9 ug/dL Reference Morning (8 a.m.) reference interval |
http://loinc.org · 2143-6 |
| S | 1979-08-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1979-09-30 | Hemoglobin [Mass/volume] in Blood | 13.4 g/dL (low) Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 1979-09-30 | Leukocytes [#/volume] in Blood by Automated count | 7 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1979-09-30 | Neutrophils [#/volume] in Blood by Automated count | 4.3 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1979-09-30 | Platelets [#/volume] in Blood by Automated count | 246 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1979-09-30 | Creatinine [Mass/volume] in Serum or Plasma | 1 mg/dL Reference 0.7-1.3 mg/dL |
http://loinc.org · 2160-0 |
| S | 1979-09-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1979-09-30 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1979-09-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 1979-09-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 1979-09-30 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1979-09-30 | Thyrotropin [Units/volume] in Serum or Plasma | 4.6 mIU/L (high) Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 1979-09-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 1979-09-30 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 1979-07-06 | Hemoglobin [Mass/volume] in Blood | 13.1 g/dL (low) Reference 13.5-17.5 g/dL |
http://loinc.org · 718-7 |
| S | 1979-07-06 | Leukocytes [#/volume] in Blood by Automated count | 5.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 1979-07-06 | Neutrophils [#/volume] in Blood by Automated count | 3.2 10*3/uL Reference 1.5-7.7 10*3/uL |
http://loinc.org · 751-8 |
| S | 1979-07-06 | Platelets [#/volume] in Blood by Automated count | 176 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1979-10-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 1979-10-21 | Total score [Mini-Cog] | 5 | http://loinc.org · 72233-0 |
| S | 1979-10-21 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1979-05-11 | Body height | 178 cm | 8302-2 | S |
| 1979-05-11 | Body weight | 77 kg | 29463-7 | S |
| 1979-05-11 | Body mass index (BMI) [Ratio] | 24.3 kg/m2 | 39156-5 | S |
| 1979-05-11 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 1979-05-11 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 1979-05-11 | Heart rate | 78 /min | 8867-4 | S |
| 1979-05-11 | Respiratory rate | 16 /min | 9279-1 | S |
| 1979-05-11 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1979-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 1979-05-26 | Body height | 178 cm | 8302-2 | S |
| 1979-05-26 | Body weight | 76.6 kg | 29463-7 | S |
| 1979-05-26 | Body mass index (BMI) [Ratio] | 24.2 kg/m2 | 39156-5 | S |
| 1979-05-26 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 1979-05-26 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 1979-05-26 | Heart rate | 80 /min | 8867-4 | S |
| 1979-05-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 1979-05-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1979-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 1979-06-24 | Body height | 178 cm | 8302-2 | S |
| 1979-06-24 | Body weight | 75.8 kg | 29463-7 | S |
| 1979-06-24 | Body mass index (BMI) [Ratio] | 23.9 kg/m2 | 39156-5 | S |
| 1979-06-24 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 1979-06-24 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 1979-06-24 | Heart rate | 74 /min | 8867-4 | S |
| 1979-06-24 | Respiratory rate | 16 /min | 9279-1 | S |
| 1979-06-24 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1979-06-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 1979-08-05 | Body height | 178 cm | 8302-2 | S |
| 1979-08-05 | Body weight | 75.2 kg | 29463-7 | S |
| 1979-08-05 | Body mass index (BMI) [Ratio] | 23.7 kg/m2 | 39156-5 | S |
| 1979-08-05 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 1979-08-05 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 1979-08-05 | Heart rate | 72 /min | 8867-4 | S |
| 1979-08-05 | Respiratory rate | 14 /min | 9279-1 | S |
| 1979-08-05 | Body temperature | 36.5 Cel | 8310-5 | S |
| 1979-08-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1979-09-30 | Body height | 178 cm | 8302-2 | S |
| 1979-09-30 | Body weight | 74.6 kg | 29463-7 | S |
| 1979-09-30 | Body mass index (BMI) [Ratio] | 23.5 kg/m2 | 39156-5 | S |
| 1979-09-30 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 1979-09-30 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 1979-09-30 | Heart rate | 76 /min | 8867-4 | S |
| 1979-09-30 | Respiratory rate | 16 /min | 9279-1 | S |
| 1979-09-30 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1979-09-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 1979-07-06 | Body height | 178 cm | 8302-2 | S |
| 1979-07-06 | Body weight | 75.6 kg | 29463-7 | S |
| 1979-07-06 | Body mass index (BMI) [Ratio] | 23.9 kg/m2 | 39156-5 | S |
| 1979-07-06 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 1979-07-06 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 1979-07-06 | Heart rate | 84 /min | 8867-4 | S |
| 1979-07-06 | Respiratory rate | 16 /min | 9279-1 | S |
| 1979-07-06 | Body temperature | 37.6 Cel | 8310-5 | S |
| 1979-07-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 1979-10-21 | Body height | 178 cm | 8302-2 | S |
| 1979-10-21 | Body weight | 75 kg | 29463-7 | S |
| 1979-10-21 | Body mass index (BMI) [Ratio] | 23.7 kg/m2 | 39156-5 | S |
| 1979-10-21 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 1979-10-21 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 1979-10-21 | Heart rate | 70 /min | 8867-4 | S |
| 1979-10-21 | Respiratory rate | 16 /min | 9279-1 | S |
| 1979-10-21 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1979-10-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Smokes a pack of cigarettes a day and has for about 35 years (35 pack-years); no cigars, vaping or cannabis. Has tried to stop twice on his own. Thinks the morning cough is just a smoker's cough
- S Retired track athlete who runs a small public relations business from home and speaks at schools, youth clubs and corporate events, often travelling; walks 3 km most mornings before the heat
- S Married; lives with his wife in a suburb of Phoenix, Arizona; three adult daughters live out of state. No relative is named or given a role in his care
- S Grew up poor in Alabama and Cleveland and met open racial exclusion at university and after the Olympics; has had money worries for much of his life and is careful about costs; Medicare with a supplemental plan
- S No clinician has ever talked to him about lung cancer screening; his last clinic checked his blood pressure and did a colonoscopy four years ago
- S Alcohol: a beer or a glass of wine once or twice a week (AUDIT-C 2); no other drug use. No known asbestos, radon or silica exposure
Functional status
- S Fully active and independent (ECOG performance status 0); walks 3 km briskly on the level and climbs three flights of stairs without stopping
Mental status
- S Alert, warm and courteous; worried about what the scan could mean; PHQ-2 1; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8
- S Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse
- S Nivolumab 360 mg intravenous infusion over 30 minutes on day 1 of each 21-day cycle, for three cycles before surgery (one 240 mg and one 120 mg vial)
- S Carboplatin 10 mg/mL injection, 525 mg (AUC 5 by the Calvert formula, creatinine clearance 80 mL/min) intravenously on day 1 of each 21-day cycle, for three cycles
- S Pemetrexed 500 mg/m2 (970 mg for a body surface area of 1.94 m2) intravenously over 10 minutes on day 1 of each 21-day cycle, for three cycles
- S Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last
- S Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed)
- S Dexamethasone 4 mg oral tablet, one tablet twice daily on the day before, the day of and the day after each pemetrexed dose
- S Ondansetron 8 mg oral tablet, one tablet every 8 hours as needed for nausea during chemotherapy
- S Acetaminophen 500 mg oral tablet, two tablets every 8 hours as needed for pain after surgery
Procedures and immunizations
Procedures
- S Shared decision-making visit for lung cancer screening with a decision aid (benefits, false positives, overdiagnosis, radiation, and the need for yearly scans and for tobacco treatment); he chose to be screened
- S Low-dose CT of the chest without contrast for lung cancer screening (first screen): solid, spiculated 2.9 cm nodule in the apicoposterior segment of the left upper lobe; enlarged left hilar lymph node 1.6 cm in short axis; mild centrilobular emphysema in both upper lobes; coronary artery calcification, moderate; Lung-RADS 4X (category 4B with additional features of malignancy)
- S Chest X-ray, posteroanterior and lateral: the left upper lobe nodule is smaller than on the screening CT; no new opacity, consolidation or ground-glass change; no effusion
- S Advance care planning conversation, about 25 minutes, with his consent
- S FDG PET-CT: avid left upper lobe nodule, 2.9 cm (SUVmax 9.8); avid left interlobar (11L) node, 1.6 cm (SUVmax 6.1); no avid mediastinal, supraclavicular or contralateral node; no distant uptake. The infrarenal abdominal aorta measures 2.1 cm
- S MRI of the brain with contrast: no metastases
- S Endobronchial ultrasound with systematic needle aspiration of stations 4R, 4L, 7, 10L and 11L under moderate sedation: adenocarcinoma in 11L (TTF-1 positive); 4R, 4L, 7 and 10L negative with adequate lymphocytes; PD-L1 (22C3) tumor proportion score 40 percent; tissue next-generation sequencing (reported in six days, with concordant plasma testing): KRAS G12C mutation, STK11 and KEAP1 wild type; no EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK or HER2 alteration
- S Thoracic multidisciplinary tumor board (thoracic surgery, medical and radiation oncology, pulmonology, radiology, pathology, nurse navigator): resectable cT1c N1 M0 stage IIB adenocarcinoma, no EGFR or ALK alteration; recommends three cycles of nivolumab with platinum doublet chemotherapy, restaging, then lobectomy
- S Pulmonary function tests: spirometry and DLCO (FEV1 2.71 L, 86 percent predicted; FEV1/FVC 0.73; DLCO 86 percent predicted). Predicted postoperative values after left upper lobectomy (14 of 19 segments remaining): FEV1 63 percent and DLCO 63 percent
- S Pulmonary rehabilitation as prehabilitation during chemoimmunotherapy: 16 supervised sessions of aerobic and strength training with breathing exercises, twice weekly
- S Restaging CT of the chest and upper abdomen with contrast after three cycles: left upper lobe nodule 1.3 cm (from 2.9 cm); left interlobar node 0.8 cm (from 1.6 cm); no new nodule, node, effusion or ground-glass change; no liver or adrenal lesion
- S Video-assisted thoracoscopic left upper lobectomy with systematic mediastinal (stations 4L, 5, 6, 7, 8, 9) and hilar lymph node dissection; three days in hospital without complications. Pathology: ypT1a N0 (0 of 16 nodes; treatment effect without viable tumor in the 11L node), 0.7 cm residual adenocarcinoma with 6 percent viable tumor (major pathologic response), margins clear (R0)
- S Pulmonary rehabilitation after lobectomy: a 12-week program, twice weekly, started
Immunizations
- S 1979-05-26: Pneumococcal conjugate vaccine PCV20, before chemoimmunotherapy
- S 1979-10-21: Influenza vaccine, high-dose, this season
- S 1979-10-21: COVID-19 mRNA vaccine, this season's formula
- S 1979-10-21: Respiratory syncytial virus vaccine, single dose
- S 1979-10-21: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D about 1920: Pneumonia at about age 7, during an epidemic in Alabama, from which he nearly died; a sickly, underweight childhood in poverty (CLM-0002)
Family history
- D brother: Died in childhood during the epidemic in which he had pneumonia; cause not recorded in the cited source
- D sister: Died in childhood during the same epidemic; cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT | 1979-05-26 | completed | PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan |
| Stop smoking completely before treatment starts and stay stopped | 1979-09-30 | completed | No cigarettes since day 1 of cycle 1, about four months; varenicline continued to complete 24 weeks |
| Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher | 1979-08-05 | completed | Three cycles on schedule; only a grade 1 rise in TSH, monitored without treatment |
| Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle | 1979-09-30 | completed | Thoracoscopic left upper lobectomy five weeks after cycle 3; R0; major pathologic response |
| Back to walking 3 km most mornings by three months after surgery | 1979-09-30 | completed | Walking 2 km a day six weeks after surgery and starting pulmonary rehabilitation |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Referral to thoracic oncology: consultation within two weeks to review the screening CT, PET-CT and EBUS results with him and plan treatment | completed | GL-NCCN-NSCLC-2026, GL-CMID-2026 |
| Work-up of the Lung-RADS 4X nodule without delay: FDG PET-CT and brain MRI with contrast this week, then endobronchial ultrasound with systematic sampling of mediastinal and hilar nodes (at least stations 4R, 4L and 7, and any PET-avid node), with enough tissue for PD-L1 and comprehensive next-generation sequencing (EGFR, ALK, ROS1, BRAF, KRAS, MET exon 14, RET, NTRK, HER2) and plasma testing in parallel; nurse navigator to track each date | completed | GL-USPSTF-LUNG-2021, GL-ACCP-SCREEN-2021, GL-ACR-LUNGRADS-2022, GL-NCCN-NSCLC-2026, GL-ACCP-STAGING-2013 |
| Tobacco treatment at every visit: brief advice, varenicline offered with a quit date, the Arizona quitline and counseling; stopping smoking improves outcomes even after a lung cancer diagnosis | completed | GL-USPSTF-TOB-2021, GL-CMID-2026 |
| Equity safeguards: a nurse navigator, written results and next steps at each visit, transport and cost help offered, and time from scan to treatment tracked against the goal | completed | GL-ALDRICH-2019, GL-BACH-1999 |
| Distress and depression screening at each visit, plain information he can share, and advance care planning when he is ready | completed | GL-CMID-2026 |
| Chemoimmunotherapy before surgery: nivolumab 360 mg with carboplatin (AUC 5) and pemetrexed 500 mg/m2 every three weeks for three cycles, with folic acid, vitamin B12 and dexamethasone premedication, hepatitis B, hepatitis C and HIV tests first, and restaging CT before surgery | completed | GL-NCCN-NSCLC-2026, GL-CHECKMATE816-2022 |
| Immune-related adverse event monitoring: TSH, free T4, liver tests, creatinine, glucose and blood count before each cycle, morning cortisol at baseline and before surgery, and a written list of warning symptoms with a 24-hour oncology line | completed | GL-ASCO-IRAE-2021, GL-CMID-2026 |
| Physiologic evaluation for lobectomy (spirometry and DLCO with predicted postoperative values) and prehabilitation: a pulmonary rehabilitation program during chemotherapy | completed | GL-ACCP-PHYS-2013, GL-CMID-2026 |
| Thoracoscopic left upper lobectomy with systematic mediastinal and hilar lymph node dissection after restaging shows response and no new disease | completed | GL-NCCN-NSCLC-2026, GL-ACCP-EARLY-2013 |
| After surgery: no further systemic therapy after a major pathologic response, by shared decision; history, examination and chest CT every six months for two to three years, then yearly low-dose CT; pulmonary rehabilitation after surgery; the KRAS G12C result kept on file for any recurrence | completed | GL-NCCN-NSCLC-2026, GL-ASCO-SURV-2020, GL-CMID-2026 |
Planned encounters
- 1979-05-11 — New patient visit: shared decision-making for lung cancer screening, same-day low-dose CT showing a suspicious left upper lobe nodule, and tobacco treatment (ENC-001)
- 1979-05-26 — Diagnosis of left upper lobe adenocarcinoma, stage IIB: thoracic oncology consultation, tumor board plan for chemoimmunotherapy before surgery, and start of varenicline (ENC-002)
- 1979-06-24 — Day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitation (ENC-003)
- 1979-07-06 — Same-day sick visit for a cold during chemoimmunotherapy (ENC-006, unscheduled)
- 1979-08-05 — After three cycles: restaging CT, decision for lobectomy, thyroid result and surgical preparation (ENC-004)
- 1979-09-30 — Six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitation (ENC-005)
- 1979-10-21 — Subsequent annual wellness visit (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Annual Wellness Visit, Subsequent
- Thoracic Oncology referral
- Thoracic Oncology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Annual Wellness Visit, Subsequent (XML)
- Thoracic Oncology referral (XML)
- Thoracic Oncology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Jesse Owens: A Lasting Legend. Growing Up | The Ohio State University Libraries | biography |
| SRC-0002 | Jesse Owens: A Lasting Legend. The Owens Family | The Ohio State University Libraries | biography |
| SRC-0003 | Jesse Owens: A Lasting Legend. Owens and The Ohio State University | The Ohio State University Libraries | biography |
| SRC-0004 | Jesse Owens: A Lasting Legend. Owens' Legacy: a National Icon | The Ohio State University Libraries | biography |
| SRC-0005 | Owens, Jesse: biographical file 2 (newspaper clippings, including UPI, AP, the Columbus Dispatch, the Ohio State Lantern and his own published account) | The Ohio State University Archives | primary |
| SRC-0006 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check screening eligibility and the shared decision-making elements, the Lung-RADS 4X work-up, EBUS staging (cT1c N1, stage IIB), the choice of three cycles of nivolumab with carboplatin and pemetrexed before surgery and of no adjuvant therapy after a major pathologic response, the predicted postoperative lung function, the handling of the grade 1 TSH rise, the exclusion of pneumonitis at the sick visit, and varenicline started after the diagnosis. |
| provenance review | not_started | He died in 1980; the recent-death rule does not apply. Claims rest on four Ohio State University Libraries exhibit pages and the Ohio State University Archives biographical clipping file. The smoking history, the documented adenocarcinoma of the left lung and the dates of admission and death are D; the screening, stage, biomarkers and treatment are synthetic. His daughters are not named. |
| safe messaging review | not_started | Tobacco claims are marked sensitive. No mental health claim is made; mood screens are synthetic and below the threshold for a safety assessment. His death is recorded once, without detail. No relative is given a role in the modern episode; the president of the 1930s is not named. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.